NCT01744223 2022-07-12
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals